RTA 408 50 Pill - green blue capsule/oblong, 22mm
Generic Name: omaveloxolone
Pill with imprint RTA 408 50 is Green / Blue, Capsule/Oblong and has been identified as Skyclarys 50 mg. It is supplied by Reata Pharmaceuticals, Inc.
Skyclarys is used in the treatment of Friedreich’s Ataxia and belongs to the drug class miscellaneous central nervous system agents. Skyclarys 50 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for RTA 408 50
Skyclarys
- Generic Name
- omaveloxolone
- Imprint
- RTA 408 50
- Strength
- 50 mg
- Color
- Green / Blue
- Size
- 22.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Miscellaneous central nervous system agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Reata Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 73179-0250
See also:
Addyi
Addyi (flibanserin) is used to treat hypoactive sexual desire disorder (HSDD) in certain women ...
Ampyra
Ampyra (dalfampridine) is used to improve walking in patients with multiple sclerosis. Includes ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Bridion
Bridion is used for reversal of neuromuscular blockade, reversal of nondepolarizing muscle relaxants
Daybue
Daybue (trofinetide) is a synthetic analog of the amino‐terminal tripeptide of IGF-1 for the t ...
Hydergine
Hydergine is used for alzheimer's disease, arteriosclerotic dementia, dementia
Inapsine
Inapsine is used for nausea/vomiting, nausea/vomiting, postoperative
Kisunla
Kisunla (donanemab) is a prescription medicine used for Alzheimer’s disease (AD) in patients with m ...
More about Skyclarys (omaveloxolone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.